EurekAlert (press release)Tianjin University makes breakthrough in synthetic genome rearrangementEurekAlert (press release)A synthetic biology team at Tianjin University (TJU) has reported new methods and strategies for genome rearrangement and acceler… Continue reading
EurekAlert (press release)Tianjin University makes breakthrough in synthetic genome rearrangementEurekAlert (press release)A synthetic biology team at Tianjin University (TJU) has reported new methods and strategies for genome rearrangement and acceler… Continue reading
EurekAlert (press release)Tianjin University makes breakthrough in synthetic genome rearrangementEurekAlert (press release)A synthetic biology team at Tianjin University (TJU) has reported new methods and strategies for genome rearrangement and acceler… Continue reading
Medgadget (blog)Global T-Cell Immunotherapy Market Growing Rapidly In Coming Years For Advanced Stage Cancer TreatmentMedgadget (blog)According to report on “Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis”, T-cell Immunotherapy i… Continue reading
|
Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR–T Manufacturing Process …
GlobeNewswire (press release) RANCHO CORDOVA, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced … |
|
Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR–T Manufacturing Process …
GlobeNewswire (press release) RANCHO CORDOVA, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced … |
|
Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR–T Manufacturing Process …
Nasdaq Cesca Therapeutics Inc. (the “Company”) develops, commercializes and markets a range of automated technologies for CAR–T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical … |